Abstract
Atypical antipsychotics have been linked to a higher risk for glucose intolerance, and consequentially the development of type 2 diabetes mellitus (DM2). We have therefore set out to investigate the acute effects of oral administration of olanzapine and ziprasidone on whole body insulin sensitivity in healthy subjects. Using the standardized hyperinsulinemic euglycemic clamp technique we compared whole body insulin sensitivity of 29 healthy male volunteers after oral intake of either olanzapine 10 mg/day (n=14) or ziprasidone 80 mg/day (n=15) for 10 days. A significant decrease (p<0.001) in whole body insulin sensitivity from 5.7 ml/h/kg (=mean, SM=0.4 ml/h/kg) at baseline to 4.7 ml/h/kg (=mean, SM=0.3 ml/h/kg) after oral intake of olanzapine (10 mg/day) for 10 days was observed. The ziprasidone (80 mg/day) group did not show any significant difference (5.2±0.3 ml/h/kg baseline vs 5.1±0.3 ml/h/kg) after 10 days of oral intake. Our main finding demonstrates that oral administration of olanzapine but not ziprasidone leads to a decrease in whole body insulin sensitivity in response to a hyperinsulinemic euglycemic challenge. Our finding is suggestive that not all atypical antipsychotics cause acute direct effects on glucose disposal and that accurate determination of side effect profile should be performed when choosing an atypical antipsychotic.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM et al (2005). Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54: 862–871.
American Diabetes Association (2004a). Diagnosis and classification of diabetes mellitus. Diabetes Care 27 (Suppl 1): S5–S10.
American Diabetes Association, A.P.A., American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004b). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.
Bergman RN (1989). Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. In Diabetes. Vol. 3, Text No. 12, pp 1512–1527 (http://diabetes.diabetesjournals.org/cgi/content/abstract/38/12/1512).
Bergman RN, Ader M (2005). Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 66: 504–514.
Bleuler M (1951). Some aspects of endocrinologic psychiatry. J Nerv Ment Dis 113: 74–76.
Boehm G, Racoosin JA, Laughren TP, Katz R (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 27: 2088–2089; author reply 2089–2090.
Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al (2004). Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl 7): 4–18; quiz 19–20.
Chintoh AMS, Lam S, Lam T, Naasasan A, Remington G, Giacca A (2006). Insulin Resistance following olanzapine administration: an animal Model. Int J Neuropsychopharmacol 9: S144.
Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC (2006). Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 29: 786–791.
Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J et al (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155: 914–920.
Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacol 20: 491–505.
De Hert M, van Eyck D, De Nayer A (2006). Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21 (Suppl 2): S11–S15.
DeFronzo RA, Tobin JD, Andres R (1979). Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–E223.
Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A et al (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26: 903–912.
Elman I, Borsook D, Lukas SE (2006). Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31: 2091–2120.
FDA (2004). MedWatch Safety Info. In Previous News Items (see http://www.fda.gov/cder/previous_news2004.htm, MedWatch Report, 13 April 2004).
Franciosi L, Kasper S, Garber A, Johnson D, Krauss R, Marder S et al (2005). Advancing the treatment of people with mental illness: A call to action in the management of metabolic issues. J Clin Psychiatry 66: 790–798.
Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D (2003). Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25: 1150–1171.
Haupt DW (2006). Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16 (Suppl 3): S149–S155.
Haupt DW, Newcomer JW (2002). Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 53: 925–933.
Haupt DW, Fahnestock PA, Flavin KA, Schweiger JA, Stevens A, Hessler MJ et al (2007). Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology (advance online publication, 21 March 2007; doi:10.1038/sj.npp.1301392).
Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O (2002). Glucose intolerance with atypical antipsychotics. Drug Saf 25: 1107–1116.
Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62: 19–28.
Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E et al (2006). Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 67: 789–797.
Holmang A, Muller M, Andersson OK, Lonnroth P (1998). Minimal influence of blood flow on interstitial glucose and lactate-normal and insulin-resistant muscle. Am J Physiol 274: E446–E452.
Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007). Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32: 289–297.
Houseknecht KL, Robertson AS, Johnson DE, Rollema H (2005). Clozapine and olanzapine, but not ziprasidone, cause acute insulin resistance in normal rats. Biol Psychiatry 57: 128.
Jansson PA, Larsson A, Smith U, Lonnroth P (1992). Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest 89: 1610–1617.
Kane JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S et al (2004). Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 65: 1447–1455.
Kapur S, Remington G (2001). Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50: 873–883.
Karter AJ, Mayer-Davis EJ, Selby JV, D'Agostino Jr RB, Haffner SM, Sholinsky P et al (1996). Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45: 1547–1555.
Kasper S, Hale A, Azorin JM, Moller HJ (1999). Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 249 (Suppl 2): II1–II14.
Kasper S, Rosillon D, Duchesne I (2001). Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 16: 179–187.
Kim FS, Huang A, Snowman MA, Teuscher C, Snyder HS (2007). Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104: 3456–3459.
Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92–100.
Koller EA, Doraiswamy PM (2002). Olanzapine-associated diabetes mellitus. Pharmacotherapy 22: 841–852.
Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J (2000). Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 157: 987–993.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1223.
Lillioja S, Bogardus C (1988). Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 4: 517–540.
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290–296.
Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Vettor R (1997). Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism 46: 123–129.
Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A, Cerveri G et al (2005). Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 20: 55–60.
Mayer-Davis EJ, Monaco JH, Hoen HM, Carmichael S, Vitolins MZ, Rewers MJ et al (1997). Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). Am J Clin Nutr 65: 79–87.
McIntyre RS, Mancini DA, Basile VS (2001). Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 62 (Suppl 23): 23–29.
Meyer J, Koro CE, L'Italien GJ (2005). The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 17: 173–180.
Meyer JM (2002). A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63: 425–433.
Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N (2000). Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 49 (Suppl 1): 5S–13S.
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001). The continuing epidemics of obesity and diabetes in the United States. Jama 286: 1195–1200.
Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL (1996). Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37: 68–73.
Muller M (2002). Science, medicine, and the future: microdialysis. BMJ 324: 588–591.
Muller M, Schmid R, Georgopoulos A, Buxbaum A, Wasicek C, Eichler HG (1995). Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 57: 371–380.
Newcomer JW (2004). Metabolic risk during antipsychotic treatment. Clin Ther 26: 1936–1946.
Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1): 1–93.
Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337–345.
Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D et al (2000). Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 49: 1255–1260.
Perry PJ, Sanger T, Beasley C (1997). Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 17: 472–477.
Ryan MC, Collins P, Thakore JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284–289.
Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley Jr C, Tollefson GD (1999). Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 156: 79–87.
Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159: 561–566.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20): 22–33; quiz 34–57.
Simpson GM (2006). Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: results of a double-blind, six-week study, with a six-month, double-blind continuation Phase. Prog Neurotherapeutics Neuropsychopharmacol 1: 149–163.
Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004). Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161: 1837–1847.
Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S et al (2003). Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 88: 5875–5880.
Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A et al (2002). Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87: 2918–2923.
Unwin N, Shaw J, Zimmet P, Alberti KG (2002). Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708–723.
Vestri HS, Maianu L, Moellering DR, Garvey WT (2006). Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32: 765–772.
Welch S, Gebhart SS, Bergman RN, Phillips LS (1990). Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71: 1508–1518.
Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C (2003). New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 59: 1–6.
Acknowledgements
The study was funded by ‘Jubilaeumsfond Oesterreichische National bank’ (no. 11067) and a research grant from Pfizer. We express our sincere gratitude to Julia Szendroedi, MD and Rupert Lanzenberger, MD, for helpful discussion and critical advice, as well as to cand med Lukas Zinnagl and Petra Zeleny for their assistance in performing the hyperinsulinemic euglycemic clamps.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sacher, J., Mossaheb, N., Spindelegger, C. et al. Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. Neuropsychopharmacol 33, 1633–1641 (2008). https://doi.org/10.1038/sj.npp.1301541
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301541


